Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O75364
UPID:
PITX3_HUMAN
Alternative names:
Homeobox protein PITX3; Paired-like homeodomain transcription factor 3
Alternative UPACC:
O75364; Q5VZL2
Background:
Pituitary homeobox 3 (PITX3), also known as Homeobox protein PITX3 and Paired-like homeodomain transcription factor 3, plays a pivotal role in the development and maintenance of meso-diencephalic dopaminergic neurons. It activates essential genes for neuron development and regulates lens development and differentiation, crucial for eye health.
Therapeutic significance:
PITX3's involvement in anterior segment dysgenesis 1 and Cataract 11, multiple types, underscores its therapeutic potential. Understanding PITX3's role could open doors to innovative treatments for these eye conditions.